蒲公英 - 制药技术的传播者 GMP理论的实践者

搜索
查看: 321|回复: 5
收起左侧

FDA对2家中国非临床测试机构的警告信

[复制链接]
药徒
发表于 2024-9-12 11:11:53 | 显示全部楼层 |阅读模式

欢迎您注册蒲公英

您需要 登录 才可以下载或查看,没有帐号?立即注册

x
https://www.fda.gov/news-events/press-announcements/fda-issues-warning-letters-two-chinese-firms-regarding-data-quality-and-integrity-concerns-violative
FDA Issues Warning Letters to Two Chinese Firms Regarding Data Quality and Integrity Concerns, Violative Lab PracticesFirms Provided Third-Party, Nonclinical Premarket Testing; Agency Review Ongoing
For Immediate Release:September 11, 2024

Today, the U.S. Food and Drug Administration issued warning letters to two Chinese nonclinical testing laboratories, citing both for laboratory oversight failures and animal care violations that raise concerns about the quality and integrity of data generated by the labs. Warning letters were issued to Mid-Link Testing Company Ltd. in Tianjin, China, and Sanitation & Environmental Technology Institute of Soochow University Ltd. in Suzhou, China. The firms provide third-party testing and validation data services to device manufacturers for use in their premarket device submissions to the FDA.
The FDA continues to conduct a rigorous review of data generated from these test facilities, submitted in premarket submissions, and does not intend to authorize submissions where the data are necessary for the FDA to make a marketing authorization decision, as such data are found to be unreliable. The agency is evaluating any impact these findings have had on past submissions and will take action to address any public health risks as necessary.
The agency inspected the firms earlier this year and found pervasive failures with data management, quality assurance, staff training and oversight. The findings included the failure to accurately record and verify key research data, which brings into question the quality and integrity of safety data collected at the facilities. These failures could lead to the use of unreliable data in premarket device submissions. The warning letters also note violations related to test animals. One firm is cited for failing to provide adequate care for the animals, and both firms failed to provide adequate identification and recording of the animals used in the labs’ testing.
“The medical device industry must be built and sustained on safety, effectiveness and quality,” said Owen Faris, Ph.D., acting director of the Office of Product Evaluation and Quality in the FDA’s Center for Devices and Radiological Health. “The FDA will take action to protect patients, consumers and the medical device supply chain from quality failures and violative practices. We strenuously remind industry of their responsibility and accountability for all data included in their submissions, which are required to comply with federal law.”
Earlier this year, the agency alerted the medical device industry to third-party testing lab concerns with device submissions and stressed the need for firms to carefully review any data from testing that the firm itself did not perform. The FDA will continue to evaluate submissions and take action where appropriate, as some devices affected may be currently on the market. The FDA will continue to focus on testing data failures, including from third-party testing labs.
Nonclinical laboratory studies are experiments in which test articles are studied prospectively in test systems (such as animals, plants and microorganisms or subparts thereof) under laboratory conditions to determine their safety. While a device sponsor may use a third-party lab for nonclinical studies, doing so does not relieve the device sponsor of the responsibility to ensure the accuracy of data included in their regulatory submission.
The FDA has requested that the recipients of the FDA warning letters notify the agency of their corrective actions to be taken within 15 working days of receiving the letters.
提到了两家检测公司,天津海河以及苏州苏大卫生与环境技术。怎么解读?目前用这两家公司做的非临床试验数据是不是不能提交FDA申报了?后面呢,整改后,以前的数据能用么?


回复

使用道具 举报

药徒
发表于 2024-9-12 11:19:15 | 显示全部楼层
本来写了很多话,想想还是算了。。。现在很多都乱套了

点评

你这个头像,不会是特朗普吧哈哈哈哈哈哈哈哈哈  详情 回复 发表于 2024-9-12 16:53
回复

使用道具 举报

药徒
发表于 2024-9-12 11:37:23 | 显示全部楼层
关于你最后提的,我认为:建议现在不要往枪口上撞,以前的数据交上去风险比较大,在重新交一次510k费再做一次申请 vs 重新做生物学实验中自己做个衡量吧,看你能承受哪一种带来的损失。另外,整改后也需要重新搭建当局、机构、厂商之间的信任,不过等他们的整改被FDA认可再说也不迟~
回复

使用道具 举报

药徒
发表于 2024-9-12 13:48:39 | 显示全部楼层
脑壳硬就去试试呗,甚至是国内提交生物学资料,都应该在短期内慎重考虑这两家机构了吧。
回复

使用道具 举报

发表于 2024-9-12 13:53:12 | 显示全部楼层
岂不是现在都得停下来整改了?坑了一帮企业
回复

使用道具 举报

药徒
发表于 2024-9-12 16:53:09 | 显示全部楼层
张_Michael 发表于 2024-9-12 11:19
本来写了很多话,想想还是算了。。。现在很多都乱套了

你这个头像,不会是特朗普吧哈哈哈哈哈哈哈哈哈
回复

使用道具 举报

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

×发帖声明
1、本站为技术交流论坛,发帖的内容具有互动属性。您在本站发布的内容:
①在无人回复的情况下,可以通过自助删帖功能随时删除(自助删帖功能关闭期间,可以联系管理员微信:8542508 处理。)
②在有人回复和讨论的情况下,主题帖和回复内容已构成一个不可分割的整体,您将不能直接删除该帖。
2、禁止发布任何涉政、涉黄赌毒及其他违反国家相关法律、法规、及本站版规的内容,详情请参阅《蒲公英论坛总版规》。
3、您在本站发表、转载的任何作品仅代表您个人观点,不代表本站观点。不要盗用有版权要求的作品,转贴请注明来源,否则文责自负。
4、请认真阅读上述条款,您发帖即代表接受上述条款。

QQ|手机版|蒲公英|ouryao|蒲公英 ( 京ICP备14042168号-1 )  京ICP证150354号  互联网药品信息服务证书编号: (京)-非经营性-2024-0033

GMT+8, 2024-9-20 15:41

Powered by Discuz! X3.4运维单位:苏州豚鼠科技有限公司

Copyright © 2001-2020, Tencent Cloud.

声明:蒲公英网站所涉及的原创文章、文字内容、视频图片及首发资料,版权归作者及蒲公英网站所有,转载要在显著位置标明来源“蒲公英”;禁止任何形式的商业用途。违反上述声明的,本站及作者将追究法律责任。
快速回复 返回顶部 返回列表